Low heparinization with heparin-bonded bypass circuits: Is it a safe strategy?

被引:39
作者
Bannan, S [1 ]
Danby, A [1 ]
Cowan, D [1 ]
Ashraf, S [1 ]
Martin, PG [1 ]
机构
[1] UNIV LEEDS,RES SCH MED,LEEDS,W YORKSHIRE,ENGLAND
关键词
D O I
10.1016/S0003-4975(96)01054-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The use of heparin-bonded cardiopulmonary bypass circuits with reduced doses of heparin sodium has been shown to give hemostatic benefits to the patient. However, fears persist that the use of less heparin may put the patient at risk for thrombotic events. This work tested the hypothesis that heparin-bonded circuits per se are effective in preserving cells and reducing thrombin generation when a reduced dose of heparin is used in vitro. Methods. Simulated extracorporeal circulation was carried out using the same unit of fresh heparinized (1.1 U/mL) human blood to simultaneously perfuse a heparin-bonded circuit and a nonbonded circuit. Samples were taken at 30, 60, 120, and 360 minutes and analyzed for markers of cell activation and thrombin generation. Results. The concentrations of platelet and white blood cell activation markers were found to be significantly lower in the heparin-bonded circuits compared with the nonbonded circuits. In addition, markers of thrombin generation were significantly lower in bonded circuits. Scanning electron microscopy revealed fewer adherent cells and less debris on the bonded surface compared with the nonbonded surface. Conclusions. Cell activation and thrombin generation were significantly reduced as a result of the presence of immobilized heparin in a system of cardiopulmonary bypass with reduced plasma heparin. However, evidence of contact activation in the bonded circuits was found after 120 minutes, indicating that anticoagulation in the system was not adequate. This becomes more important clinically where the extrinsic pathway of coagulation is also involved. (C) 1997 by The Society of Thoracic Surgeons.
引用
收藏
页码:663 / 668
页数:6
相关论文
共 24 条
  • [1] BOISCLAIR MD, 1993, BLOOD, V82, P3350
  • [2] COMPLEMENT ACTIVATION BEFORE, DURING AND AFTER CARDIOPULMONARY BYPASS
    BONSER, RS
    DAVE, JR
    JOHN, L
    GADEMSETTY, MK
    CARTER, PG
    DAVIES, E
    TAYLOR, P
    GAYA, H
    LENNOX, SC
    VERGANI, D
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1990, 4 (06) : 291 - 296
  • [3] DECREASED BLOOD-LOSS AFTER CARDIOPULMONARY BYPASS USING HEPARIN-COATED CIRCUIT AND 50-PERCENT REDUCTION OF HEPARIN DOSE
    BOROWIEC, J
    THELIN, S
    BAGGE, L
    HULTMAN, J
    HANSSON, HE
    [J]. SCANDINAVIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1992, 26 (03): : 177 - 185
  • [4] BOROWIEC J, 1992, J THORAC CARDIOV SUR, V104, P642
  • [5] BRASH JL, 1988, BLOOD, V71, P932
  • [6] PLATELET AND NEUTROPHIL ACTIVATION IN CARDIOPULMONARY BYPASS
    COLMAN, RW
    [J]. ANNALS OF THORACIC SURGERY, 1990, 49 (01) : 32 - 34
  • [7] Courtney James M., 1994, Perfusion, V9, P3, DOI 10.1177/026765919400900102
  • [8] SURFACE-BOUND HEPARIN - PANACEA OR PERIL
    EDMUNDS, LH
    [J]. ANNALS OF THORACIC SURGERY, 1994, 58 (02) : 285 - 286
  • [9] Elstad M R, 1995, Curr Opin Hematol, V2, P47
  • [10] Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass
    Gorman, RC
    Ziats, NP
    Rao, AK
    Gikakis, N
    Sun, L
    Khan, MMH
    Stenach, N
    Sapatnekar, S
    Chouhan, V
    Gorman, JH
    Niewiarowski, S
    Colman, RW
    Anderson, JM
    Edmunds, LH
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1996, 111 (01) : 1 - 11